> Detailanzeige

Maertens, Johan; Logan, Aaron C.; Jang, Junho; Long, Gwynn; Tang, Jih-Luh; Hwang, William Y. K.; Koh, Liang Piu; Chemaly, Roy; Gerbitz, Armin; Winkler, Julia; Yeh, Su-Peng; Hiemenz, John; Christoph, Sandra; Lee, Dong-Gun; Wang, Po-Nan; Holler, Ernst; Mielke, Stephan; Akard, Luke; Yeo, Adeline; Ramachandra, Sangana; Smith, Kristin; Pertel, Peter; Segal, Florencia

Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation
  • Beteiligte: Maertens, Johan; Logan, Aaron C.; Jang, Junho; Long, Gwynn; Tang, Jih-Luh; Hwang, William Y. K.; Koh, Liang Piu; Chemaly, Roy; Gerbitz, Armin; Winkler, Julia; Yeh, Su-Peng; Hiemenz, John; Christoph, Sandra; Lee, Dong-Gun; Wang, Po-Nan; Holler, Ernst; Mielke, Stephan; Akard, Luke; Yeo, Adeline; Ramachandra, Sangana; Smith, Kristin; Pertel, Peter; Segal, Florencia
  • Erschienen: American Society for Microbiology, 2020
  • Erschienen in: Antimicrobial Agents and Chemotherapy
  • Sprache: Englisch
  • DOI: 10.1128/aac.02467-19
  • ISSN: 0066-4804; 1098-6596
  • Schlagwörter: Infectious Diseases ; Pharmacology (medical) ; Pharmacology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>Human cytomegalovirus (HCMV) can cause significant disease in immunocompromised patients, and treatment options are limited by toxicities. CSJ148 is a combination of two anti-HCMV human monoclonal antibodies (LJP538 and LJP539) that bind to and inhibit the functions of viral HCMV glycoprotein B (gB) and the pentameric complex, consisting of glycoproteins gH, gL, UL128, UL130, and UL131. In this phase 2, randomized, placebo-controlled trial, we evaluated the safety and efficacy of CSJ148 for prophylaxis of HCMV in patients undergoing allogeneic hematopoietic stem cell transplantation.</jats:p>
  • Zugangsstatus: Freier Zugang